Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia.

Dominique Larrey,Laura D'Erasmo, Sallyann O'Brien,Marcello Arca

Liver international : official journal of the International Association for the Study of the Liver（2023）

引用 2|浏览9

暂无评分

摘要

These data indicate that the hepatic safety of lomitapide remains favourable with no clinically significant elevations in hepatic biomarkers and hepatic stiffness remained normal for more than 9 years follow-up. PHASE 3 TRIAL: NCT00730236; extension phase: NCT00943306; LOWER: NCT02135705.

查看译文

关键词

Lomitapide,hepatic,hepatic biomarkers,hepatic steatosis,homozygous familial hypercholesterolaemia,liver,liver fibrosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要